Recent studies (46) have demonstrated that Astragaloside IV (AS-IV) can suppress the expression of NLRP3, Caspase-1, GSDMD, IL-1β, and IL-18, thereby mitigating podocyte cell death in diabetic nephropathy (DN). The gene discussed is IL18; the disease is liver dysplastic nodule.